Target- |
MechanismVirus internalization inhibitors |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date21 Dec 2020 |
|
MechanismProtective antigen inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date14 Dec 2012 |
100 Clinical Results associated with Emergent Manufacturing Operations Baltimore LLC
0 Patents (Medical) associated with Emergent Manufacturing Operations Baltimore LLC
100 Deals associated with Emergent Manufacturing Operations Baltimore LLC
100 Translational Medicine associated with Emergent Manufacturing Operations Baltimore LLC